Meta AnalysisID 4518
川芎嗪对动物模型动脉粥样硬化的作用与机制：一项Meta分析与系统评价
CRD42021288874
we will evaluate the efficacy and summarized the mechanism of ligustrazine in animal models with atherosclerosis. Context and rationale Epidemiological surveys show that the prevalence of cardiovascular disease in people
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4518
- Evidence Id
- 13076
- Core Evidence Id
- 13076
- Source Meta Analysis Id
- 4487
- Herb2 Meta Analysis Id
- HBMA004487
- Crd Id
- CRD42021288874
- Title
- The Role and Mechanism of Ligustrazine for Atherosclerosis in Animal Models: A Meta-Analysis and Systematic Review
- Review Question
- we will evaluate the efficacy and summarized the mechanism of ligustrazine in animal models with atherosclerosis. Context and rationale Epidemiological surveys show that the prevalence of cardiovascular disease in people over 20 years old is 48%, which is one of the main causes of death in the global population. Atherosclerosis（AS） is an important pathological basis for inducing cardiovascular and cerebrovascular diseases, and the incidence of cardiovascular and cerebrovascular diseases related to it continues to rise and is younger trend. Therefore, it is of great clinical significance to actively explore the pathological mechanism of AS and effective treatment options.Ligusticum wallichii (Chuanxiong) is the dried rhizome of Ligusticum chuanxiong Hort., first recorded in the earliest complete Pharmacopoeia of China (Shennong's Classic of Materia Medica) from Warring States period to Han Dynasty.In traditional Chinese Medicine (TCM), it is thought to activate blood and promote Qi . For thousands of years, it has been widely used for treatment of cardiovascular diseases .Ligustrazine is the active ingredient of Ligusticum wallichii that was first isolated in 1957. Since then, it has been studied in treatment of diseases such as coronary heart disease.Recent studies reported that Lig was effective in the treatment of AS on account of several pharmacological properties: anti-inflammatory, antioxidant, antifibrosis and immunomodulatory.Nevertheless, scattered evidence and uncertain mechanisms limit the clinical use of Lig for treatment of AS. Systematic review and meta-analysis of preclinical studies are considered to be valuable tools to provide insights into the validity of animal studies,improving the precision of estimated effects, and supporting further generalization to human clinical trials.
- Study Type Included
- Inclusion criteria: Controlled studies assessing the effects of ligustrazine on animal models with AS were searched. No language, publication date, or publication status restrictions will be imposed. Exclusion criteria: All case reports , clinical trials , reviews, and in vitro studies , cross-over studies, studies without a separate control group.
- Condition Being Studied
- Participant
- Animal
- Inclusion criteria: Laboratory animal models of Atherosclerosis of any age, sex, or strain that were established in any manner will be included. Exclusion criteria: NO atherosclerosis model or atherosclerosis models with diabetes, hypertension and other diseases are excluded.
- Human Disease Modelled
- Atherosclerosis is the main pathological basis of various cardiovascular and cerebrovascular diseases, and cardiovascular and cerebrovascular diseases are the most common clinical diseases.
- Intervention
- Inclusion criteria: The use of any type of ligustrazine intervention compared with a placebo control will be included. Exclusion criteria: Studies that combined multipletherapies will be excluded.
- Comparator Control
- Inclusion criteria: Placebo controls included equivalent amounts of non-functional substances (e.g., saline), or no treatment. Exclusion criteria: Studies that comparisoned with other traditional Chinese medicines will be excluded.
- Main Outcome
- Outcome Measure
- Inclusion criteria: Plaque area and Blood lipids reported Exclusion criteria: no relevant outcomes reported
- Additional Outcome
- Study Method
- Keyword
- Animals; Atherosclerosis; Models, Animal; Pyrazines; tetramethylpyrazine
- Contact
- Li Sijin [email protected]
- Organisational Affiliation
- Shanghai University of Traditional Chinese Medicine
- Funding Source
- Scientific Research Project of Science and Technology Commission of Shanghai Nunicipality(No.18401900200);Health and Family Planning Scientific Research Project of Shanghai Pudong New Area Health and Family Planning Commission (No.PW2018D-11);Research Project of Traditional Chinese Medicine of Shanghai Municipal Health Commission (No.2020LQ013) Grant number(s) No.18401900200;No.PW2018D-11;No.2020LQ013
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Pre-clinical animal intervention review
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-11-09
- Registration Date
- 2021-12-10
- Anticipated Start Date
- 2021-11-01
- Anticipated Completion Date
- 2022-02-01
- Title Cn
- 川芎嗪对动物模型动脉粥样硬化的作用与机制：一项Meta分析与系统评价
- Title En
- The Role and Mechanism of Ligustrazine for Atherosclerosis in Animal Models: A Meta-Analysis and Systematic Review
- Bilingual Status
- complete